Ophthalmology

At its core, gene therapy is a form of medicine that fixes or replaces malfunctioning genes the biological instructions inside your cells rather than just treating symptoms. When applied to the retina (the light-sensing layer at the back of the eye), gene therapy aims to restore normal visual function at a molecular level.

Rather than glasses or surgery, this approach delivers healthy genetic material directly into retinal cells so they can make the proteins they’re missing the ones vital for capturing and transmitting visual signals.

At its core, gene therapy is a form of medicine that fixes or replaces malfunctioning genes the biological instructions inside your cells rather than just treating symptoms. When applied to the retina (the light-sensing layer at the back of the eye), gene therapy aims to restore normal visual function at a molecular level.

Rather than glasses or surgery, this approach delivers healthy genetic material directly into retinal cells so they can make the proteins they’re missing the ones vital for capturing and transmitting visual signals.

Traditional treatments for retinal diseases often slow progression without reversing loss. But many retinal conditions are caused by single-gene defects meaning the problem starts with a specific broken instruction in your DNA. That makes them ideal candidates for gene therapy.

Here’s why the excitement is real:

• Precision: Targets the root genetic cause, not just symptoms.
• Longer-lasting benefit: A single treatment can provide sustained improvement.
• Less invasive than systemic medicine: Delivered locally into the eye.
• Potential to preserve or even restore vision.

Essentially, we’re shifting from a model of management to one of correction.

Gene therapy isn’t yet a universal cure but it’s already a game-changer for several retinal conditions, especially those caused by specific genetic mutations.

Conditions Where Gene Therapy Is Leading the Way

• Leber Congenital Amaurosis (LCA); a group of inherited disorders causing severe vision loss from infancy.
• Retinitis Pigmentosa (RP); a family of genetic diseases leading to gradual degeneration of the retina.
• Stargardt Disease; an inherited form of macular degeneration affecting central vision.
• Choroideremia; a rare X-linked disorder that can cause progressive blindness.

Some therapies have already been approved by regulatory agencies and are helping people see better, while many others are in clinical trials. Because these diseases are genetically distinct, gene therapy is tailored to specific mutations making genetic testing and counselling a critical step.

Gene therapy involves several key steps think of it as a carefully choreographed delivery mission:

1. Identify the Genetic Target
Researchers first determine which gene isn’t working correctly. This usually happens through genetic testing and clinical evaluation.
2. Build the Gene Therapy “Package”
A correct copy of the gene is packaged inside a viral vector. Scientists use harmless viruses — most commonly adeno-associated viruses (AAVs) because they’re great at entering cells without causing disease.
3. Delivery Into the Eye
The therapy is injected into the eye, typically through:
• Subretinal injection: under the retina — precise but technically demanding.
• Intravitreal injection: into the cavity of the eye — less invasive.
The therapy enters the target cells, and the healthy gene begins making the correct protein.
4. Cells Start Functioning Better
Once the gene is working again, retinal cells can produce essential proteins, potentially slowing disease progression and in some cases, improving vision.